Loading...
XSHG
600252
Market cap891mUSD
Jul 10, Last price  
1.97CNY
1D
3.68%
1Q
-23.94%
Jan 2017
-56.99%
IPO
76.92%
Name

Guangxi Wuzhou Zhongheng Group Co.

Chart & Performance

D1W1MN
XSHG:600252 chart
P/E
P/S
3.59
EPS
Div Yield, %
0.53%
Shrs. gr., 5y
-1.84%
Rev. gr., 5y
-13.81%
Revenues
1.75b
-23.00%
325,007,828285,783,099628,166,157712,395,8881,397,574,7701,150,551,2651,945,718,4523,996,697,6413,214,406,3891,343,085,1451,670,061,9912,047,709,2753,298,765,2833,814,056,0853,676,393,7023,161,843,6452,713,769,8383,096,542,0522,270,823,1871,748,586,406
Net income
-357m
L-5.28%
20,717,89336,578,76047,007,169125,709,148398,574,986374,929,597683,921,043742,515,8841,594,536,443520,158,888489,356,691604,914,996613,351,979744,951,597562,819,969306,918,69979,025,46584,308,795-376,979,139-357,088,533
CFO
-19m
L
199,414,43140,754,22259,467,3750191,734,9910906,427,707945,099,660569,946,797291,525,5051,495,621,750893,214,443853,399,912654,312,676656,615,88400484,100,303477,427,055-18,907,983
Dividend
Jun 24, 20240.01 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Guangxi Wuzhou Zhongheng Group Co., Ltd., operating from Wuzhou, China, specializes in the research, development, manufacturing, and distribution of pharmaceutical products across the nation. The company's diverse range of medicinal preparations includes pills, capsules, injections, and tablets, formulated to address various health concerns such as cardiovascular and cerebrovascular disorders, physical injuries, gynecological conditions, and respiratory ailments. In addition to its core pharmaceutical business, Guangxi Wuzhou Zhongheng Group also produces health food items, notably under its DOUBLE MONEY brand. Furthermore, its offerings encompass health-oriented functional beverages, various forms of turtle paste (including smokable and jelly types), and other related wellness products.
IPO date
Nov 30, 2000
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT